spironolactone has been researched along with Hypertrophy in 34 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "Aldosterone caused a 27% increase in protein incorporation (EC(50) = 40 nmol/L) and a 29% increase in myocyte surface area compared with the vehicle control." | 5.32 | Aldosterone directly stimulates cardiac myocyte hypertrophy. ( Lorell, BH; Nakayama, M; O'Connell, TD; Okoshi, K; Okoshi, MP; Schuldt, AJ; Simpson, PC; Yan, X, 2004) |
| " Intracellular Na+ was measured using sodium-binding-benzofuran-isophthalate as a fluorescent sodium indicator, and cardiac hypertrophy was assessed using B-type natriuretic peptide transcription and (3)H-leucine incorporation." | 3.73 | Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. ( Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sakamoto, T; Shono, M; Suzuki, S; Yamamuro, M; Yasue, H; Yoshimura, M, 2006) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "Streptozotocin-induced renal fibrosis, PAI-1 expression, TGF-beta1 expression, and macrophage infiltration occur via mineralocorticoid receptor, and spironolactone ameliorates renal fibrosis presumably via the inhibition of macrophage infiltration, PAI-1 expression, and TGF-beta1 expression in streptozotocin-induced early diabetic injury." | 3.72 | Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2004) |
| "Pre-treatment with eplerenone or Y27632 prevented the aldosterone-induced cell hypertrophy, actin polymerization, the increase in alpha-SMA expression and the increases of collagen type I, III, IV mRNA levels in RMCs." | 1.35 | Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. ( Diah, S; Gang, L; Hamid, MR; Hitomi, H; Kimura, S; Nagai, Y; Nishiyama, A; Tamiya, T; Zhang, GX; Zhang, W, 2008) |
| "Aldosterone caused a 27% increase in protein incorporation (EC(50) = 40 nmol/L) and a 29% increase in myocyte surface area compared with the vehicle control." | 1.32 | Aldosterone directly stimulates cardiac myocyte hypertrophy. ( Lorell, BH; Nakayama, M; O'Connell, TD; Okoshi, K; Okoshi, MP; Schuldt, AJ; Simpson, PC; Yan, X, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (38.24) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 13 (38.24) | 29.6817 |
| 2010's | 6 (17.65) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Zhang, W | 2 |
| Na, J | 1 |
| Huo, Y | 1 |
| Wang, Y | 1 |
| Liu, K | 1 |
| Shah, AM | 1 |
| Shah, SJ | 1 |
| Anand, IS | 1 |
| Sweitzer, NK | 1 |
| O'Meara, E | 1 |
| Heitner, JF | 1 |
| Sopko, G | 1 |
| Li, G | 1 |
| Assmann, SF | 1 |
| McKinlay, SM | 1 |
| Pitt, B | 1 |
| Pfeffer, MA | 1 |
| Solomon, SD | 1 |
| Araujo, CM | 1 |
| Hermidorff, MM | 1 |
| Amancio, Gde C | 1 |
| Lemos, Dda S | 1 |
| Silva, ME | 1 |
| de Assis, LV | 1 |
| Isoldi, MC | 1 |
| Diah, S | 1 |
| Zhang, GX | 1 |
| Nagai, Y | 1 |
| Gang, L | 1 |
| Kimura, S | 1 |
| Hamid, MR | 1 |
| Tamiya, T | 1 |
| Nishiyama, A | 2 |
| Hitomi, H | 2 |
| Sakurabayashi-Kitade, S | 1 |
| Aoka, Y | 1 |
| Nagashima, H | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Kawana, M | 1 |
| Arias-Loza, PA | 1 |
| Muehlfelder, M | 1 |
| Elmore, SA | 1 |
| Maronpot, R | 1 |
| Hu, K | 1 |
| Blode, H | 1 |
| Hegele-Hartung, C | 1 |
| Fritzemeier, KH | 1 |
| Ertl, G | 1 |
| Pelzer, T | 1 |
| Yoshida, Y | 1 |
| Morimoto, T | 1 |
| Takaya, T | 1 |
| Kawamura, T | 1 |
| Sunagawa, Y | 1 |
| Wada, H | 1 |
| Fujita, M | 1 |
| Shimatsu, A | 1 |
| Kita, T | 1 |
| Hasegawa, K | 1 |
| Susic, D | 1 |
| Varagic, J | 1 |
| Frohlich, ED | 1 |
| Mavrakanas, TA | 1 |
| Cheva, A | 1 |
| Kallaras, K | 1 |
| Karkavelas, G | 1 |
| Mironidou-Tzouveleki, M | 1 |
| Sherajee, SJ | 1 |
| Fujita, Y | 1 |
| Rafiq, K | 1 |
| Nakano, D | 1 |
| Mori, H | 1 |
| Masaki, T | 1 |
| Hara, T | 1 |
| Kohno, M | 1 |
| Kambara, A | 1 |
| Holycross, BJ | 1 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 1 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Tsybouleva, N | 1 |
| Zhang, L | 1 |
| Chen, S | 1 |
| Patel, R | 1 |
| Lutucuta, S | 1 |
| Nemoto, S | 1 |
| DeFreitas, G | 1 |
| Entman, M | 1 |
| Carabello, BA | 1 |
| Roberts, R | 1 |
| Marian, AJ | 1 |
| Fujisawa, G | 1 |
| Okada, K | 1 |
| Muto, S | 1 |
| Fujita, N | 1 |
| Itabashi, N | 1 |
| Kusano, E | 1 |
| Ishibashi, S | 1 |
| Okoshi, MP | 1 |
| Yan, X | 1 |
| Okoshi, K | 1 |
| Nakayama, M | 2 |
| Schuldt, AJ | 1 |
| O'Connell, TD | 1 |
| Simpson, PC | 1 |
| Lorell, BH | 1 |
| Yamamuro, M | 1 |
| Yoshimura, M | 1 |
| Abe, K | 1 |
| Shono, M | 1 |
| Suzuki, S | 1 |
| Sakamoto, T | 1 |
| Saito, Y | 1 |
| Nakao, K | 1 |
| Yasue, H | 1 |
| Ogawa, H | 1 |
| Neves, MF | 1 |
| Amiri, F | 1 |
| Virdis, A | 1 |
| Diep, QN | 1 |
| Schiffrin, EL | 1 |
| Guo, C | 1 |
| Martinez-Vasquez, D | 1 |
| Mendez, GP | 1 |
| Toniolo, MF | 1 |
| Yao, TM | 1 |
| Oestreicher, EM | 1 |
| Kikuchi, T | 1 |
| Lapointe, N | 1 |
| Pojoga, L | 1 |
| Williams, GH | 1 |
| Ricchiuti, V | 1 |
| Adler, GK | 1 |
| Franco, V | 1 |
| Chen, YF | 1 |
| Feng, JA | 1 |
| Li, P | 1 |
| Wang, D | 1 |
| Hasan, E | 1 |
| Oparil, S | 1 |
| Perry, GJ | 1 |
| Yuan, J | 1 |
| Jia, R | 1 |
| Bao, Y | 1 |
| Hastings, NB | 1 |
| McEwen, BS | 1 |
| Fleshner, M | 1 |
| Deak, T | 1 |
| Nguyen, KT | 1 |
| Watkins, LR | 1 |
| Maier, SF | 1 |
| Gayral, MN | 1 |
| Millet, D | 1 |
| Netter, A | 1 |
| Matsuo, K | 1 |
| Kawai, K | 1 |
| Tsuchiyama, H | 1 |
| Ueki, Y | 1 |
| Goodman, AD | 1 |
| Vagnucci, AH | 1 |
| Hartroft, PM | 1 |
| Sutherland, LE | 1 |
| Hartroft, P | 1 |
| Balis, JU | 1 |
| Bailey, JD | 1 |
| Lynch, MJ | 1 |
| Desmit, EM | 1 |
| Cost, WS | 1 |
| Brown, JJ | 1 |
| Fraser, R | 1 |
| Lever, AF | 1 |
| Robertson, JI | 1 |
| Arant, BS | 1 |
| Brackett, NC | 1 |
| Young, RB | 1 |
| Still, WJ | 1 |
| Ramanathan, K | 1 |
| Gantt, C | 1 |
| Grossman, A | 1 |
| Modlinger, RS | 1 |
| Nicolis, GL | 1 |
| Krakoff, LR | 1 |
| Gabrilove, JL | 1 |
| Schmidt, P | 1 |
| Kopsa, H | 1 |
| Kronenberg, KH | 1 |
| Meyer, D | 1 |
| Zazgornik, J | 1 |
| Kotzaurek, R | 1 |
| Neumann, E | 1 |
| Gekle, D | 1 |
| Wernze, H | 1 |
| Langer, KH | 1 |
| Fanconi, A | 1 |
| Schachenmann, G | 1 |
| Nüssli, R | 1 |
| Prader, A | 1 |
| Hofmann, LM | 1 |
| Sagartz, JW | 1 |
| Gall, G | 1 |
| Vaitukaitis, J | 1 |
| Haddow, JE | 1 |
| Klein, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
1 trial available for spironolactone and Hypertrophy
33 other studies available for spironolactone and Hypertrophy
| Article | Year |
|---|---|
Spironolactone Inhibits Cardiomyocyte Hypertrophy by Regulating the Ca
Topics: Animals; Calcineurin; Calcium; Hypertrophy; Myocytes, Cardiac; NFATC Transcription Factors; Rats; Sp | 2021 |
Rapid effects of aldosterone in primary cultures of cardiomyocytes - do they suggest the existence of a membrane-bound receptor?
Topics: A Kinase Anchor Proteins; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Egtazic Acid; | 2016 |
Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells.
Topics: Aldosterone; Amides; Animals; Cell Transdifferentiation; Collagen; Eplerenone; Gene Expression Regul | 2008 |
Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice.
Topics: Aldosterone; Angiotensin II; Animals; Female; Hyperplasia; Hypertension; Hypertrophy; Male; Mice; Mi | 2009 |
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hy | 2009 |
Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Chlorocebus aethiops; COS Cells; Disease Models, An | 2010 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2010 |
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Creatinine; Diabetes Mellitus, Experimental; Diab | 2010 |
Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
Topics: Aldosterone; Animals; Aorta, Thoracic; Blood Pressure; Cells, Cultured; Chimera; Eplerenone; Glucose | 2012 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Immunohisto | 2004 |
Aldosterone directly stimulates cardiac myocyte hypertrophy.
Topics: Aldosterone; Animals; Animals, Newborn; Cells, Cultured; Culture Media, Serum-Free; Dexamethasone; E | 2004 |
Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.
Topics: Aldosterone; Amides; Animals; Benzofurans; Cells, Cultured; Eplerenone; Hemodynamics; Hypertrophy; I | 2006 |
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Collagen; Ectodysplasins; Fibrosis; Heart; Hypertension | 2005 |
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2006 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy | 2006 |
Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glutathione Peroxida | 2007 |
Characterization of adrenal hormone binding sites in the prairie vole.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Androstanols; Animals; Arginine Vasopressin | 1997 |
Endogenous glucocorticoids play a positive regulatory role in the anti-keyhole limpet hemocyanin in vivo antibody response.
Topics: Administration, Oral; Adrenalectomy; Animals; Antigens; Corticosterone; Dexamethasone; Drug Combinat | 2001 |
[Ovarian hyperstimulation syndrome. Notes on the physiopathology and treatment apropos of 3 cases].
Topics: Adult; Ascites; Capillary Permeability; Chorionic Gonadotropin; Female; Gonadotropins, Pituitary; Hu | 1975 |
Glucocorticoid-suppressible hyperaldosteronism. Ultrastructural observation of a case.
Topics: Adrenal Cortex; Aldosterone; Dexamethasone; Endoplasmic Reticulum; Female; Humans; Hyperaldosteronis | 1985 |
Pathogenesis of Bartter's syndrome.
Topics: Adrenal Gland Diseases; Adrenocorticotropic Hormone; Albumins; Aldosterone; Alkalosis; Angiotensin I | 1969 |
Bartter's syndrome. A report of four cases, including three in one sibship, with comparative histologic evaluation of the juxtaglomerular apparatuses and glomeruli.
Topics: Alkalosis; Angiotensin II; Blood Pressure; Carbon Dioxide; Cerebrospinal Fluid Proteins; Electrolyte | 1970 |
An unusual type of hypokalaemic alkalosis with a disturbance of renin and aldosterone.
Topics: Adolescent; Adrenal Cortex Hormones; Albumins; Aldosterone; Alkalosis; Angiotensin II; Creatinine; D | 1970 |
Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets--Bartter's syndrome or disease?
Topics: Aldosterone; Alkalosis; Angiotensin II; Bone Diseases; Child; Child, Preschool; Humans; Hyperaldoste | 1970 |
Six year follow-up of a child with Bartter syndrome.
Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema | 1973 |
Some observations on the pathogenesis of Bartter's syndrome.
Topics: Adult; Aldosterone; Alkalosis; Angiotensin II; Blood Volume; Drug Therapy, Combination; Humans; Hype | 1973 |
[Bartter's syndrome in adults. Case report with light- and electron-microscopic findings].
Topics: Adult; Alkalosis; Female; Humans; Hyperaldosteronism; Hyperplasia; Hypertrophy; Hypokalemia; Hypoten | 1973 |
[Problems in Bartter's syndrome].
Topics: Alkalosis; Biopsy; Child, Preschool; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; | 1971 |
Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ("Bartter's syndrome"), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment.
Topics: Alkalosis; Calcium; Child; Chronic Disease; Female; Growth Disorders; Humans; Hyperaldosteronism; Hy | 1971 |
Effects of hydrochlorothiazide, spironolactone and metyrapone on electrolyte excretion and zona glomerulosa width in the sodium depleted rat.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Medulla; Animals; Diet, Sodium-Restricted; Hydrochlo | 1970 |
Erythrocyte Na flux in a patient with Bartter's syndrome.
Topics: Aldosterone; Alkalosis; Ammonium Chloride; Biological Transport; Biological Transport, Active; Cell | 1971 |